title: Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.
abstract: The abnormal vasculature of the tumor microenvironment supports progression and resistance to treatment. Judicious application of antiangiogenic therapy may normalize the structure and function of the tumor vasculature, promoting improved blood perfusion. However, direct clinical evidence is lacking for improvements in blood perfusion after antiangiogenic therapy. In this study, we used MRI to assess tumor blood perfusion in 30 recurrent glioblastoma patients who were undergoing treatment with cediranib, a pan-VEGF receptor tyrosine kinase inhibitor. Tumor blood perfusion increased durably for more than 1 month in 7 of 30 patients, in whom it was associated with longer survival. Together, our findings offer direct clinical evidence in support of the hypothesis that vascular normalization can increase tumor perfusion and help improve patient survival.
authors: AA. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA 02129, USA. sorensen@nmr.mgh.harvard.edu
authors: A Gregory
authors: AG
authors: Sorensen
authors: Kyrre E
authors: KE
authors: Emblem
authors: Pavlina
authors: P
authors: Polaskova
authors: Dominique
authors: D
authors: Jennings
authors: Heisoog
authors: H
authors: Kim
authors: Marek
authors: M
authors: Ancukiewicz
authors: Meiyun
authors: M
authors: Wang
authors: Patrick Y
authors: PY
authors: Wen
authors: Percy
authors: P
authors: Ivy
authors: Tracy T
authors: TT
authors: Batchelor
authors: Rakesh K
authors: RK
authors: Jain
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D018572:Disease-Free Survival; D005909:Glioblastoma / Q000098:blood supply* / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008279:Magnetic Resonance Imaging; D009364:Neoplasm Recurrence, Local / Q000098:blood supply* / Q000188:drug therapy*; D011799:Quinazolines / Q000627:therapeutic use*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D015996:Survival Rate; D007211:Indoles
chemical_list: D020533:Angiogenesis Inhibitors; D011799:Quinazolines; D040262:Receptors, Vascular Endothelial Growth Factor; C500926:cediranib; D007211:Indoles